These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19954248)

  • 1. Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites.
    Shamovsky I; de Graaf C; Alderin L; Bengtsson M; Bladh H; Börjesson L; Connolly S; Dyke HJ; van den Heuvel M; Johansson H; Josefsson BG; Kristoffersson A; Linnanen T; Lisius A; Männikkö R; Nordén B; Price S; Ripa L; Rognan D; Rosendahl A; Skrinjar M; Urbahns K
    J Med Chem; 2009 Dec; 52(23):7706-23. PubMed ID: 19954248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
    Shamovsky I; Connolly S; David L; Ivanova S; Nordén B; Springthorpe B; Urbahns K
    J Med Chem; 2008 Mar; 51(5):1162-78. PubMed ID: 18257512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).
    Ghosh S; Elder A; Guo J; Mani U; Patane M; Carson K; Ye Q; Bennett R; Chi S; Jenkins T; Guan B; Kolbeck R; Smith S; Zhang C; LaRosa G; Jaffee B; Yang H; Eddy P; Lu C; Uttamsingh V; Horlick R; Harriman G; Flynn D
    J Med Chem; 2006 May; 49(9):2669-72. PubMed ID: 16640325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration.
    Connolly S; Skrinjar M; Rosendahl A
    Biochem Pharmacol; 2012 Mar; 83(6):778-87. PubMed ID: 22209712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
    Myokai T; Ryu S; Shimizu H; Oiki S
    Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
    Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
    Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
    Masetti M; Cavalli A; Recanatini M
    J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.
    Washburn DG; Hoang TH; Frazee JS; Johnson L; Hammond M; Manns S; Madauss KP; Williams SP; Duraiswami C; Tran TB; Stewart EL; Grygielko ET; Glace LE; Trizna W; Nagilla R; Bray JD; Thompson SK
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4664-8. PubMed ID: 19616429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
    Imai YN; Ryu S; Oiki S
    J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4633-7. PubMed ID: 16782336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
    Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
    Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
    Cho K; Ando M; Kobayashi K; Miyazoe H; Tsujino T; Ito S; Suzuki T; Tanaka T; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4781-5. PubMed ID: 19596193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.
    Gadhe CG; Balupuri A; Cho SJ
    J Biomol Struct Dyn; 2015; 33(11):2491-510. PubMed ID: 25617117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
    Ermondi G; Visentin S; Caron G
    Eur J Med Chem; 2009 May; 44(5):1926-32. PubMed ID: 19110341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
    McIntyre CJ; McCauley JA; Bednar B; Bednar RA; Butcher JW; Claremon DA; Cunningham ME; Freidinger RM; Gaul SL; Homnick CF; Koblan KS; Mosser SD; Romano JJ; Liverton NJ
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5132-5. PubMed ID: 19648007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
    Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
    Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.
    Slee DH; Moorjani M; Zhang X; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Jalali K; Sai Y; Zuo Z; Yang C; Wen J; O'Brien Z; Petroski R; Saunders J
    J Med Chem; 2008 Mar; 51(6):1730-9. PubMed ID: 18307293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8.
    Jensen PC; Nygaard R; Thiele S; Elder A; Zhu G; Kolbeck R; Ghosh S; Schwartz TW; Rosenkilde MM
    Mol Pharmacol; 2007 Aug; 72(2):327-40. PubMed ID: 17652183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
    Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.